Assessment of the humoral immune response and safety of reduced doses of influenza vaccine administered intradermally compared to intramuscular administration

Trial Profile

Assessment of the humoral immune response and safety of reduced doses of influenza vaccine administered intradermally compared to intramuscular administration

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2015

At a glance

  • Drugs Influenza virus vaccine liposomal (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Berna Biotech
  • Most Recent Events

    • 08 Jul 2009 Status changed from unconfirmed to completed as reported by ISRCTN: Current Controlled Trials.
    • 02 Jun 2009 Influenza virus vaccine identified as influenza virus vaccine liposomal
    • 22 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top